Page last updated: 2024-10-30

metformin and Graves Disease

metformin has been researched along with Graves Disease in 2 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Graves Disease: A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).

Research Excerpts

ExcerptRelevanceReference
"The objective of the study was to describe the clinical and biochemical findings of four patients with chronic hypothyroidism, previously euthyroid on fixed doses of L-T4 for several years, in whom the metformin was initiated."3.73Thyrotropin suppression by metformin. ( Filmore-Nassar, A; Glass, AR; Vigersky, RA, 2006)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vigersky, RA1
Filmore-Nassar, A1
Glass, AR1
Watts, NB1
Blevins, LS1

Other Studies

2 other studies available for metformin and Graves Disease

ArticleYear
Thyrotropin suppression by metformin.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Interactions; Female; Goiter; Graves D

2006
Endocrinology.
    JAMA, 1996, Jun-19, Volume: 275, Issue:23

    Topics: Bone Resorption; Endocrinology; Graves Disease; Humans; Hyperparathyroidism; Hypoglycemic Agents; Me

1996